Unlock the curative potential of Hematopoietic Stem Cell Transplantation by reducing infections and GvHD
ProTcell, the first ever T cell Progenitors based biotherapy
A new generation of drug transplant product with a cell therapy statuts
Smart Immune is the first clinical-stage biotherapeutics company focused on delivering the rapid, multipotent curative power of T Cell Progenitors to reboot Immune system to Patient affected by Severe blood cancers or blood inherited diseases .
We are bringing the T Cell Progenitors, a new generation of T cell medicine to Patients in life threatening conditions. Once transplanted to patient, those cells called ProTcells, differentiate quickly into mature T cell in thymus recipient to reboot immune system and ensure a fast, multipotent protection from all pathogens and cancer cells.
Smart Immune patented ProTcell platform technology is applicable to all cell and gene therapies involving T cells, enabling fast improved clinical outcome for patients. With one clinical trial on Severe combined immuno-deficiencies already in clinic, two clinical trials for Acute Leukemia to be initiated by the end of 2020 and a milli-fluidic automation project enabling bioproduction scalability, Smart Immune aims to make HSCT medicine safer, more effective, and more affordable.
Based in Paris, Smart Immune integrates a collaboration with Necker Enfants Malades Hospital cell and gene therapy teams bringing ground-breaking scientific, clinical and development expertise. With the demonstrated track records of its founders, Marina Cavazzana, MD, PhD, and Isabelle André, PhD, Smart Immune is committed to change Patient prognosis.
T Cell are the most efficient weapons for fighting life threatening infections and cancers
What if we could provide them to patients without adverse events ?
Bringing HSCT curative power without adverse events to patients in life threatening conditions
T Cell Progenitors: a new generation of Transplant drug product leading to reduced infections and GvHD risks
A rapid efficiency without adverse events reducing the number of hospitalization days
Automated platform enabling bioproduction Scale up and Scale out
Our latest news and updates
Pr Cavazzana elected American National Academy of Medicine member
On October 21, 2019, Professor Marina Cavazzana has been elected to the National Academy of Medicine (NAM). A new distinction for this committed Physician-researcher.
“The success of the first clinical trials convinced me that I absolutely had to overcome the obstacles encountered and continue my research for the benefit of young patients.”
Smart Immune research is housed in the Imagine institute
Smart Immune research team is hosted in the Imagine institute of genetic diseases to implement its research and development activity.
A € 1.88 m non dilutive grant for Cell manufacturing automation
Smart Immune has been designated Winner of the Innovation Competition organised by the BPI as part of the PIA III investment plan a has been awarded a non-dilutive grant of 1.88 m euros over 3 years to co-finance its cell manufacturing automation programme.